SLAM
INDV icon

Swiss Life Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Swiss Life Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
11,945
-7,089
-37% -$257K ﹤0.01% 968
2026
Q1 		$605K Buy
19,034
+9,742
+105% +$322K ﹤0.01% 795
2025
Q4 		$333K Buy
+9,292
New +$284K ﹤0.01% 976

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Swiss Life Asset Management's INDV Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Indivior Pharmaceuticals (INDV) stake by 37% in Q2 2026, selling an estimated $257K and leaving 11,945 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Swiss Life Asset Management first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. The position peaked at $605K in Q1 2026. 199 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Swiss Life Asset Management held 11,945 shares of Indivior Pharmaceuticals worth $490K as of Q2 2026.
  • Swiss Life Asset Management sold 7,089 Indivior Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #968 holding.
  • Swiss Life Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Swiss Life Asset Management's Indivior Pharmaceuticals position peaked at $605K in Q1 2026.
  • 199 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.